IDEAYA Biosciences Inc

詳細情報 IDEAYA Biosciences Inc 企業名

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

企業情報

企業コードIDYA

会社名IDEAYA Biosciences Inc

上場日May 23, 2019

設立日2015

最高経営責任者「CEO」Mr. Yujiro S. Hata

従業員数131

証券種類Ordinary Share

決算期末May 23

本社所在地7000 Shoreline Ct, Suite 350

都市SOUTH SAN FRANCISCO

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号94080

電話番号16504436209

ウェブサイトhttps://www.ideayabio.com/

企業コードIDYA

上場日May 23, 2019

設立日2015

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Joshua Bleharski, Ph.D.

Chief Financial Officer

--

Dr. Catherine J. Mackey, Ph.D.

Independent Director

--

Dr. M. Garret Hampton, Ph.D.

Independent Director

--

Dr. Terry J. Rosen, Ph.D.

Independent Chairman of the Board

--

Dr. Darrin Beaupre, M.D., Ph.D.

Chief Medical Officer

--

Dr. Jeffrey L. (Jeff) Stein, Ph.D.

Independent Director

--

Mr. Andres Ruiz Briseno, CPA

Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations

--

Dr. Michael A. White, Ph.D.

Chief Scientific Officer

--

Ms. Wendy L. Yarno

Independent Director

--

Mr. Yujiro S. Hata

President, Chief Executive Officer, Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Joshua Bleharski, Ph.D.

Chief Financial Officer

--

Dr. Catherine J. Mackey, Ph.D.

Independent Director

--

Dr. M. Garret Hampton, Ph.D.

Independent Director

--

Dr. Terry J. Rosen, Ph.D.

Independent Chairman of the Board

--

Dr. Darrin Beaupre, M.D., Ph.D.

Chief Medical Officer

--

Dr. Jeffrey L. (Jeff) Stein, Ph.D.

Independent Director

--

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2024

FY2024Q4

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

事業別USD

会社名

収益

比率

WRN

7.00M

0.00%

MAT2A

0.00

0.00%

Pol Theta

0.00

0.00%

地域別USD

会社名

収益

比率

United States

7.00M

100.00%

事業別

地域別

事業別USD

会社名

収益

比率

WRN

7.00M

0.00%

MAT2A

0.00

0.00%

Pol Theta

0.00

0.00%

株主

更新時刻: Tue, Jul 1

株主統計

種類

株主統計

比率

Fidelity Management & Research Company LLC

14.99%

BlackRock Institutional Trust Company, N.A.

8.17%

Janus Henderson Investors

7.31%

The Vanguard Group, Inc.

5.80%

Federated Hermes Global Investment Management Corp.

5.44%

Other

58.29%

株主統計

比率

Fidelity Management & Research Company LLC

14.99%

BlackRock Institutional Trust Company, N.A.

8.17%

Janus Henderson Investors

7.31%

The Vanguard Group, Inc.

5.80%

Federated Hermes Global Investment Management Corp.

5.44%

Other

58.29%

種類

株主統計

比率

Investment Advisor

45.54%

Investment Advisor/Hedge Fund

33.49%

Hedge Fund

21.64%

Venture Capital

8.56%

Research Firm

4.37%

Individual Investor

0.91%

Pension Fund

0.77%

Sovereign Wealth Fund

0.59%

Bank and Trust

0.34%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

444

101.86M

116.30%

-6.31M

2025Q1

454

97.81M

111.68%

-11.15M

2024Q4

442

95.26M

108.96%

-7.87M

2024Q3

426

95.20M

112.79%

+2.56M

2024Q2

409

85.26M

112.59%

-3.91M

2024Q1

388

81.45M

108.91%

-1.44M

2023Q4

351

68.31M

105.94%

-512.62K

2023Q3

331

61.92M

105.66%

-3.64M

2023Q2

313

59.35M

103.37%

+5.88M

2023Q1

290

47.36M

97.90%

-6.95M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Fidelity Management & Research Company LLC

13.13M

14.99%

+167.11K

+1.29%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

7.15M

8.17%

+286.75K

+4.18%

Mar 31, 2025

Janus Henderson Investors

6.40M

7.31%

+544.14K

+9.29%

Mar 31, 2025

The Vanguard Group, Inc.

5.08M

5.8%

+14.54K

+0.29%

Mar 31, 2025

Federated Hermes Global Investment Management Corp.

4.77M

5.44%

-295.60K

-5.84%

Mar 31, 2025

Point72 Asset Management, L.P.

4.41M

5.04%

+4.27M

+3048.93%

Jun 06, 2025

Logos Global Management LP

3.50M

4%

+500.00K

+16.67%

Mar 31, 2025

State Street Global Advisors (US)

3.45M

3.93%

+125.33K

+3.77%

Mar 31, 2025

T. Rowe Price Associates, Inc.

3.39M

3.87%

-395.42K

-10.45%

Mar 31, 2025

Deerfield Management Company, L.P.

3.27M

3.73%

+531.55K

+19.43%

Mar 31, 2025

詳細を見る

25.020USD

IDEAYA Biosciences Inc

25.020

概要

企業名

金融